

# MEDICAL PHYSICS AND QUALITY ASSURANCE IN PARTICLE THERAPY

---

Markus Stock

Head Medical Physics @ MedAustron Ion Therapy Centre

Prof Medical Physics in Particle Therapy

**KARL  
LANDSTEINER**   
PRIVATUNIVERSITÄT FÜR  
GESUNDHEITSWISSENSCHAFTEN

# OVERVIEW

- Introduction
  - Differences to photons
- Particle Therapy Treatment Planning
  - Differences
  - LET and RBE
  - Guidelines
- Quality Assurance
  - Beam Delivery and other equipment
- Conclusion

# INTRODUCTION





# BEAM PRODUCTION


- Electron Linear Accelerator

vs.


p, C Synchrotron



# FUNDAMENTAL DIFFERENCE IN PENETRATION




# THE PRINCIPLE OF PARTICLE THERAPY



# TREATMENT PLANNING - COMPARISON

## PHOTONS


IMRT, VMAT, SBRT



Several fields, entry and exit dose

## PROTONS


IMPT



Fewer fields, reduced entry dose, no exit dose

## DOSE DIFFERENTIAL

Photons minus Protons



# TREATMENT PLANNING





# PRESCRIBING AND REPORTING

## ICRU REPORT 78: DOSE QUANTITIES AND UNITS

- Absorbed (physical) dose:
  - Symbol:  **$D$**  (total absorbed dose)  
 **$d$**  (absorbed dose per fx)
  - Unit: **1 Gy**
- RBE-weighted absorbed dose:
  - Symbol:  **$D_{\text{RBE}}$**  (total RBE-weighted absorbed dose)  
 **$d_{\text{RBE}}$**  (RBE-weighted absorbed dose per fx)
  - Unit: **1 Gy (RBE)**

# PRESCRIBING AND REPORTING

## ICRU REPORT 78: DOSE QUANTITIES AND UNITS

### ● RBE-WEIGHTED ABSORBED DOSE ( $D_{RBE}$ )

Relation between absorbed dose ( $D$ ) and RBE-weighted absorbed dose ( $D_{RBE}$ ) for protons:

$$D_{RBE} = 1.1 * D$$

- RBE is a dimensionless quantity. Therefore, both  $D$  and  $D_{RBE}$  share the unit Gy.
- To avoid confusion, it is recommended that the quantity  $D_{RBE}$  shall be expressed in Gy, followed by a space and the parenthetical descriptor '(RBE)'.


# TWO RBE MODELS APPLIED CLINICALLY FOR C

	<b>NIRS Clinical dose</b>	<b>Local effect model I (LEM I)</b>
Developed at	NIRS, Chiba, Japan	GSI, Darmstadt, Germany
Developed for	Passive scattering beam delivery	Active scanning beam delivery
1st patient treated	1994	1997
Total no. Treated, Dec-19	26.000	8.000
Purpose	Predict tumor response (acute effect)	Predict late side effects
Cell type	HSG cell line	Chordoma cell line
Ref. Radiation	(Photons) – indirectly via neutron experience	Photon
Dose dependent RBE	No	Yes

# TWO RBE MODELS APPLIED CLINICALLY FOR C


**Local effect model I ( $D_{LEM I}$ )**  
8.000 patients treated

**NIRS clinical dose ( $D_{NIRS}$ )**  
26.000 patients treated



# NIRS CLINICAL DOSE VS. LEM I

In Japan:  
 $D_{\text{NIRS}} = 3.6 \text{ Gy (RBE)}$



Adapted from G Magro et al. PMB (2017)

# TREATMENT PLANNING SOFTWARE


## CT CALIBRATION

### ● CT – Basis for dose calculation

- HUs depend on CT imaging protocol parameters
- HU (to MD) to WET: Conversion table need to be selected
- Imaging protocol specific calibration required



CT



Example of HU to MD conversion table.

# TREATMENT PLANNING SOFTWARE




## DOSE CALCULATION

☀ 3 families :

1) Ray tracing

2) Pencil beam

3) Monte Carlo




**A. Mazal Utrecht 2016**



# TREATMENT PLANNING SOFTWARE DOSE CALCULATION ALGORITHMS

## Pencil beam algorithm




- ✓ **Fast, pragmatic**
- Less sensitive to complex geometries
- Weaknesses in the presence of lateral heterogeneities
- Weaknesses in the modelling of nuclear halo
  - *Attention: combination of larger air gaps, range shifter, lateral heterogeneities and oblique surfaces (H&N, lung)*

- Time consuming
- ✓ **High accuracy**
- Semi-analytic implementations in commercial TPS
  - Pre-calculated beam model
  - Scoring starts e.g. at patient surface




# RANGE UNCERTAINTIES EFFECTS

MV photons




Protons/carbon ions



# RANGE UNCERTAINTIES SOURCES


## Range uncertainty




- Estimated sum of range uncertainties: ~3 - 5%
- Range uncertainties are likely to be systematic.

# RANGE UNCERTAINTY

- SPR dependency on RED and mean ionization potential cannot be fully resolved by a single CT scan
  - Direct SPR estimation via DECT
  - Algorithms for RED/I value estimation DECT




- Remaining uncertainty due to:
  - Artefacts
  - Size dependent calibration
  - I-value
  - SPR energy dependency



# PLAN GENERATION STRATEGIES

## SFO vs MFO: ISODOSE DISTRIBUTIONS



ICRU Report 78

# PLAN GENERATION STRATEGIES

## ROBUSTNESS EVALUATION

Patient position uncertainty

Use isotropic uncertainty

Superior [cm] 0.20

Right [cm] 0.20

Posterior [cm] 0.20

Anterior [cm] 0.20

Inferior [cm] 0.20

Left [cm] 0.20

Patient shifts [cm]:

R-L	I-S	P-A
0.20	0.00	0.00
-0.20	0.00	0.00
0.00	0.00	0.20
0.00	0.00	-0.20
0.00	0.20	0.00
0.00	-0.20	0.00

Density uncertainty

Density uncertainty [%]: 3.50

Number of discretization points: 2

Density shifts [%]: -3.50 3.50

*The density uncertainty is modeled by scaling the mass density of the patient and is uniform for all beams*

Total number of scenarios: 12

Total number of dose computations: 12

Compute scenario doses

Scenario definition




DVHs for all scenarios

# PLAN GENERATION STRATEGIES

ROBUST OPTIMIZATION & FIELD MATCHING / PATCHING

## Match fields




Lateral penumbra

+

Lateral penumbra

## Patch fields



Distal penumbra

+


Lateral/distal penumbra

# NON-ISOCENTRIC PROTON TREATMENTS



**Non-isocentric proton treatments allow reducing proton penumbras!**

**Up to 30-40% penumbra reduction clinically!**



**Non-Isocenter – 50 cm closer to nozzle**


Grevillot et al MedPhys 2020



# PHYSICAL BEAM PROPERTIES

## SPOT SIZE / PENUMBRA




- dosmetic impact of air gap reduction





# DIFFERENCE BETWEEN PROTONS AND CARBONS

- Sharp penumbra maintained in depth
- Fragmentation tail
- High LET in last part of the path



Weber and Kraft, Cancer J 2009


# RE-IRRADIATION SCENARIO

**From 78 to 16 Gy RBE in 10 mm ( > 6 Gy RBE per mm)**




# BIOLOGICAL IMPACT

Photons




Carbons





DNA double helix



# CARBON IONS HIGH LET - ONLY WHERE YOU NEED IT?





# Is CIRT dealing with high $LET_d$ ?



# NOVEL TREATMENT PLAN EVALUATION CONCEPT IN CIRT BASED ON HIGH-LET-DOSE

- High-LET-dose (hLD physical dose filtered on LET) quantity with potential to be additional evaluator in TP
- compared the hLD distribution in small and large tumors
- 10 patients having either  $<500 \text{ cm}^3$  small (n=5) or  $\geq 500 \text{ cm}^3$  as large tumor
- voxel-based evaluation of fraction of hLD to physical dose (hLDf) as a function of LET threshold was performed


## 30 keV/um appropriate threshold?





# HIGH LET dose objective

*LET<sub>d</sub> distribution: what can be achieved?*

Original – LET optimized



increase high LET dose – e.g the dose which has a LET beyond 40 keV/μm should be more than 15 Gy



# QUALITY ASSURANCE





# QA EQUIPMENT/MEASUREMENT DEVICES

For Beam-commissioning



Daily QA and Patient specific QA





Grevillot et al Med Phys. 2018 Jan;45(1):352-369

# QA TABLE




● Faster

● Easier


● Prototype



# ESTABLISH OPTIMIZATION OF QA




- Integrated system for both proton and carbon ions and generate trendlines



		Protons		Carbon ions	
Sphinx/Lynx region	QA parameter	Warning	Fail	Warning	Fail
Spot	Beam position (x,y)	1.5 mm	3 mm	1.5 mm	3 mm
	Beam size (x,y)	20%/2mm	30%/3mm	20%/2mm	40%/3mm
Bragg peak	Distal range	1 mm	2 mm	1 mm	2 mm
	Proximal range	1 mm	2 mm	1 mm	2 mm
	Width	1 mm	2 mm	1 mm	2 mm
	Fall-off	1 mm	2 mm	1 mm	2 mm
Central fiducial	Coincidence (x,y)	1.5 mm	3 mm		
Homogeneity	Homogeneity (1D)	3%	6%	3%	6%
Dose	Dose	2%	3%	2%	3%


# PPVS DAILY QA





# PAS WHOLE WORKFLOW

## IGRT accuracy



### Daily check


With whole clinical workflow with intended wrong position

Check of markers on the cube with laserlines after registration and alignment

1 Position: T180°

- **Tolerance level: 0.5 mm**
- **Action level 1: 1.0 mm**
- **Action level 2: 2.0 mm**


# OPERATION SCHEDULE



# PILLARS OF BEAM TIME REDUCTION FOR QA

## I. OPTIMIZATION

(optimizing QA procedures with beam)



*In use since March 2019*

**First worldwide routine use of  
Sphinx for carbon ions!**

## II. SUBSTITUTION

(replacing QA procedures with beam by other means)

Reimagining patient-specific QA in proton and ion therapy facilities

26 May 2021. Sponsored by IFA Dostmety

Medical physicists from the Austrian particle therapy centre MedAustron explain how – and why – they've put an independent QA solution at the heart of their patient treatment programme



*In use since February 2021*

**First worldwide clinical user of  
myQAion!**

# MOTIVATION TOWARDS INDEPENDENT DOSE CALCULATION

- **Rationale**

- expQA (experimental QA) requires a lot of beam time!
- expQA is performed in a homogeneous geometry – not representative of the patient!
- **expQA is less sensitive in detecting treatment failures than IDC!**

- **IMRT:**

IDC was 12 times more sensitive at detecting treatment failures for IMRT than measurement-based PSQA. [Kry et al, Med Phys 2019](#)

- **Cyberknife:**

similar findings in terms of sensitivity. [Milder et al, J Appl Clin Med Phys, 2020](#)

- **Protons:**


“The implementation of a Monte Carlo (MC) algorithm in an IDC system was shown to illuminate dose computation issues from analytical algorithms implemented in TPS, which would not otherwise be detected using traditional measurement-based PSQA.” [Jhonson et al, PloSOne 2019](#)



# PSQA AT MEDAUSTRON



- PSQA set-up for horizontal beam

Horizontal beam



Positioning via tracking camera

Entrance window




24 pinpoints block  
*(placed at the treatment position in water)*

# PROTON INDEPENDENT DOSE CALCULATION

- MyQA iON (IBA-Dosimetry)

## Workflow

- TPS plan exported to MyQAiON
- **Automatic** IDC recalculation (*Monte Carlo algorithm*) & gamma evaluation in the background
- After **10min-1hr**, IDC analysis review and IDC report generated to approve the treatment (**web-browser-based technology**)




3D Dose and Gamma verification of the TPS plan dose vs. independent MC plan dose on patient anatomy: 3D Gamma map (upper left), dose difference map (upper right), TPS plan dose (lower right), independent MC plan dose (lower left).

<https://www.iba-dosimetry.com/product/myqa-ion-pt>

# PROTON INDEPENDENT DOSE CALCULATION

## PSQA reduction



# OPTIMIZATION OF MACHINE QA

## Goal

### **REDUCING QA BEAM TIME**

- INCREASING MP QA EFFICIENCY
- SUBSTITUTING BEAM QA BY OTHER MEANS

## Boundaries

### **KEEP QUALITY**


- NO SAFETY COMPROMISES

# SUMMARY ON QA OPTIMIZATION

## I. OPTIMIZATION

2019

- Ultra-Fast Morning QA V1!



2021

- Ultra-Fast Morning QA V2!  
*VBL QA speed-up (~10 min saved daily)*

2023

- Ultra-Fast Morning QA V3!  
*1-energy dose QA  
Sphinx compact*



2024

- Ultra-Fast Morning QA V4?

## II. SUBSTITUTION

- IDC HBLp + VBLp  
(myQAiON)!
- IDEAL v1.0!



- IDC IR4 (myQAiON) – preponed!
- myDEAL (HBLc + VBLc) –  
*alpha/beta?*

- myDEAL (HBLc + VBLc) –  
*clinical?*

2024+ : Log-file based QA ?

# AREAS OF RESEARCH AT MEDAUSTRON



Clinical • Translational

# RESEARCH AT MEDAUSTRON



## CLINICAL RESEARCH

- **Registry study**
- **Clinical studies**


Creating more evidence in particle therapy



## INTERDISCIPLINARY ONCOLOGY RESEARCH

- **Radiation Oncology**
- **Medical Physics**

Teaching and research site of the Karl Landsteiner Private University



## TRANSLATIONAL & SCIENTIFIC RESEARCH

- **Radiation Biology**
- **Med. Radiation Physics**
- **Accelerator Physics**
- **Particle Physics**

In cooperation with Medical Universities Vienna & Graz, Technical University Vienna, HEPHY and FH Wr. Neustadt



# INTERDISCIPLINARY ONCOLOGY RESEARCH

At the Department of General and Translational Oncology  
and Hematology at Karl Landsteiner University



**Prof. Markus Stock**

*Division:*  
**Medical Physics**

Development/optimization of medical physics methods including dosimetry and microdosimetry, MC simulations, Big Data, radiation plan optimization, software development and process management



**Prof. Piero Fossati**

*Division:*  
**Radiation Oncology**

Optimization of patient treatments with radiotherapy by applying the best standards of care and by performing clinical research and fostering the translation of preclinical research in a clinical setting

# VACANCIES

## KARL LANDSTEINER UNIVERSITY OF HEALTH SCIENCES/MEDAUSTRON

- **POSTDOCTORAL RESEARCH FELLOW (POST DOC) DIVISION „RADIATION ONCOLOGY“** - UNIV. PROF. DR. PIERO FOSSATI MD
  - 40 Hours (F/M/D)
- **PHD Position - DIVISION „RADIATION ONCOLOGY“** - UNIV. PROF. DR. PIERO FOSSATI MD
  - 30 Hours (F/M/D)
- **PHD Position - DIVISION „MEDICAL PHYSICS“** - UNIV.-PROF. PD DI MARKUS STOCK, PHD
  - 30 Hours (F/M/D)
- Workplace: MedAustron in Wiener Neustadt
- For more details contact: [markus.stock@medaustron.at](mailto:markus.stock@medaustron.at)

# TRANSLATIONAL RESEARCH


## RESEARCH STRATEGY 2022 - 2024

### Applied Particle and Medical Physics

- Particle Imaging
- Instrumentation
- Dose Determination
- Microdosimetry
- Laboratory Course

### Biophysics and Molecular Radiobiology

- Pre-clinical Animal Research
- Translational Radiobiology



Exploratory Studies and Emerging Topics

### Technological Innovations and Clinical Implementation

- Clinical Implementation and Validation
- MRI in Particle Therapy
- Quality Assurance

### Accelerator Physics

- Implementation of Helium Ions
- Extraction Mechanisms
- Novel Developments

# SUMMARY

- Particle Therapy requires **additional specialization** of at least 6 months in medical physics (TP, special equipment, QA)
- Synchrotron possibility to take advantage of **Multi-Ion treatment** at one single site
- Effort in design and requirements definition to get **best of several particles**
- Many **optimization efforts** still ongoing (organizational, expansion of indications, dosimetric uncertainty, LET, beamline design, ...) and a lot of **research possibilities**

MANY THANKS FOR YOUR ATTENTION